Effect of SARS-CoV-2 Infection and Infection Severity on Longer-Term Glycemic Control and Weight in People With Type 2 Diabetes.

"Duality of Interest. T.S. receives salary support from the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Takeda, AbbVie, and Boehringer Ingelheim) and from a generous contribution from Dr. Nancy A. Dreyer of IQVia to the Department of Epidemiology, University of North Carolina at Chapel Hill. T.S. does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, and Novo Nordisk. J.S.T. discloses receiving investigator-initiated grant support from Novo Nordisk on behalf of the Trustees of the University of Pennsylvania. J.D.M. reports consulting fees from MannKind and Medtronic Diabetes. He receives investigator-initiated research funding from Dexcom. J.B.B.’s effort is contracted for consulting and clinical trials by the University of North Carolina by Novo Nordisk, Dexcom, Sanofi, Tolerion, and vTv Therapeutics; he has received compensation for consulting from Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, CeQur, Cirius Therapeutics, Dasman Diabetes Institute and Research Center (Kuwait City, Kuwait), Eli Lilly, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, Lilly, MannKind, Mediflix, MedImmune, Medscape, Mellitus Health, Moderna, Pendulum Therapeutics, Praetego, Stability Health, Valo, and Zealand Pharma; and he has stock/options in Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, and Stability Health. No other potential conflicts of interest relevant to this article were reported."

"Funding. This work was supported by National Center for Advancing Translational Sciences (NCATS) grant U24 TR002306 (R.W., R.V., M.A.H., R.M.). J.S.T. was supported, in part, by National Institutes of Health/National Institute of Diabetes, Digestive, and Kidney Diseases Mentored Patient Oriented Research Award (K23DK116935). J.B.B. was supported in part by grants from the National Institutes of Health (NCATS grant UL1TR002489 and Foundation for the National Institutes of Health grant P30DK124723). T.S. receives investigator-initiated research funding and support as principal investigator (R01 AG056479) from the National Institute on Aging and as co-investigator (R01 HL118255, R01 MD011680), National Institutes of Health. He also receives salary support as Director of Comparative Effectiveness Research, NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR002489)."